Does the media prefer NERV or SDGR?

In the previous week, Schrodinger had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Minerva Neurosciences. Schrodinger's average media sentiment score of 1.15 beat Minerva Neurosciences' score of 1.09 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NERV or PHAR?

In the previous week, Pharming Group had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Pharming Group and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.09 beat Pharming Group's score of 0.27 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, CGEM or NERV?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is CGEM or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Minerva Neurosciences N/A N/A -32.63%

Does the media favor CGEM or NERV?

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 2 articles in the media. Minerva Neurosciences' average media sentiment score of 1.09 beat Cullinan Therapeutics' score of 1.02 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or NERV?

In the previous week, Kura Oncology had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Kura Oncology and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.09 beat Kura Oncology's score of -0.62 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Minerva Neurosciences (NERV) Competitors

$4.68 -0.07 (-1.47%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$4.91 +0.23 (+5.00%)

As of 04:05 AM Eastern

Compare

NERV vs. SDGR, PHAR, CGEM, KURA, and ABUS

Should you buy Minerva Neurosciences stock or one of its competitors? MarketBeat compares Minerva Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Minerva Neurosciences include Schrodinger (SDGR), Pharming Group (PHAR), Cullinan Therapeutics (CGEM), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does Minerva Neurosciences compare to Schrodinger?

Minerva Neurosciences (NASDAQ:NERV) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Minerva Neurosciences has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Minerva Neurosciences' return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Schrodinger	-40.61%	-30.85%	-15.32%

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Schrodinger had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Minerva Neurosciences. Schrodinger's average media sentiment score of 1.15 beat Minerva Neurosciences' score of 1.09 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Minerva Neurosciences has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

Minerva Neurosciences currently has a consensus target price of $10.50, indicating a potential upside of 124.36%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 35.63%. Given Minerva Neurosciences' higher possible upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Schrodinger has higher revenue and earnings than Minerva Neurosciences. Schrodinger is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Schrodinger	$255.87M	4.31	-$103.26M	-$1.41	N/A

Summary

Schrodinger beats Minerva Neurosciences on 11 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Pharming Group?

Minerva Neurosciences (NASDAQ:NERV) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Pharming Group has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Pharming Group	$376.13M	2.30	$2.85M	$0.16	76.50

Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 124.36%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 213.18%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 3.30% compared to Minerva Neurosciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Pharming Group	3.30%	4.64%	2.55%

In the previous week, Pharming Group had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Pharming Group and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.09 beat Pharming Group's score of 0.27 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Minerva Neurosciences has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

Summary

Pharming Group beats Minerva Neurosciences on 13 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

Cullinan Therapeutics currently has a consensus target price of $30.75, indicating a potential upside of 102.17%. Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 124.36%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 2 articles in the media. Minerva Neurosciences' average media sentiment score of 1.09 beat Cullinan Therapeutics' score of 1.02 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Minerva Neurosciences' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Minerva Neurosciences	N/A	N/A	-32.63%

Summary

Cullinan Therapeutics beats Minerva Neurosciences on 7 of the 12 factors compared between the two stocks.

How does Minerva Neurosciences compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

34.6% of Minerva Neurosciences shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kura Oncology has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market.

Kura Oncology presently has a consensus price target of $25.90, suggesting a potential upside of 199.25%. Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 124.36%. Given Kura Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kura Oncology is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Kura Oncology had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Kura Oncology and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.09 beat Kura Oncology's score of -0.62 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Minerva Neurosciences has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Minerva Neurosciences' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Minerva Neurosciences	N/A	N/A	-32.63%

Kura Oncology has higher revenue and earnings than Minerva Neurosciences. Kura Oncology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.39	-$278.67M	-$3.35	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Summary

Kura Oncology beats Minerva Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Arbutus Biopharma?

Minerva Neurosciences (NASDAQ:NERV) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Minerva Neurosciences has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

In the previous week, Minerva Neurosciences had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Minerva Neurosciences' score of 1.09 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Minerva Neurosciences	Positive
Arbutus Biopharma	Positive

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 124.36%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 14.94%. Given Minerva Neurosciences' higher probable upside, equities analysts plainly believe Minerva Neurosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arbutus Biopharma has a net margin of 83.95% compared to Minerva Neurosciences' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arbutus Biopharma has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24

Summary

Arbutus Biopharma beats Minerva Neurosciences on 11 of the 13 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221.30M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.16	17.69	22.17	24.18
Price / Sales	N/A	302.27	525.94	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	-1.44	3.85	9.88	6.72
Net Income	-$293.42M	$75.85M	$3.57B	$337.19M
7 Day Performance	-6.40%	-3.99%	-2.45%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	152.97%	19.65%	26.51%	33.10%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	2.5592 of 5 stars	$4.68 -1.5%	$10.50 +124.4%	+166.7%	$221.30M	N/A	N/A	9
SDGR Schrodinger	3.2256 of 5 stars	$13.15 -1.1%	$20.25 +54.0%	-34.8%	$970.73M	$255.87M	N/A	790	Positive News Gap Down
PHAR Pharming Group	3.7803 of 5 stars	$13.62 +8.1%	$38.33 +181.4%	+5.4%	$961.84M	$376.13M	85.13	280
CGEM Cullinan Therapeutics	3.4961 of 5 stars	$15.46 +11.7%	$30.75 +98.9%	+69.8%	$950.17M	N/A	N/A	30	Gap Up
KURA Kura Oncology	2.1873 of 5 stars	$10.41 -7.5%	$26.38 +153.4%	+34.8%	$924.10M	$67.48M	N/A	130	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. SDGR, PHAR, CGEM, KURA, and ABUS

How does Minerva Neurosciences compare to Schrodinger?

Summary

How does Minerva Neurosciences compare to Pharming Group?

Summary

How does Minerva Neurosciences compare to Cullinan Therapeutics?

Summary

How does Minerva Neurosciences compare to Kura Oncology?

Summary

How does Minerva Neurosciences compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. SDGR, PHAR, CGEM, KURA, and ABUS

How does Minerva Neurosciences compare to Schrodinger?

Is NERV or SDGR more profitable?

Do insiders and institutionals have more ownership in NERV or SDGR?

Does the media prefer NERV or SDGR?

Which has more risk & volatility, NERV or SDGR?

Do analysts recommend NERV or SDGR?

Which has better valuation & earnings, NERV or SDGR?

Summary

How does Minerva Neurosciences compare to Pharming Group?

Which has better earnings and valuation, NERV or PHAR?

Do analysts prefer NERV or PHAR?

Is NERV or PHAR more profitable?

Does the media refer more to NERV or PHAR?

Do institutionals and insiders hold more shares of NERV or PHAR?

Which has more volatility & risk, NERV or PHAR?

Summary

How does Minerva Neurosciences compare to Cullinan Therapeutics?

Which has better valuation & earnings, CGEM or NERV?

Which has more risk and volatility, CGEM or NERV?

Do analysts recommend CGEM or NERV?

Do insiders & institutionals have more ownership in CGEM or NERV?

Does the media favor CGEM or NERV?

Is CGEM or NERV more profitable?

Summary

How does Minerva Neurosciences compare to Kura Oncology?

Do institutionals & insiders hold more shares of KURA or NERV?

Which has more risk and volatility, KURA or NERV?

Do analysts rate KURA or NERV?

Does the media favor KURA or NERV?

Is KURA or NERV more profitable?

Which has better earnings and valuation, KURA or NERV?

Summary

How does Minerva Neurosciences compare to Arbutus Biopharma?

Which has more risk and volatility, NERV or ABUS?

Does the media favor NERV or ABUS?

Do analysts rate NERV or ABUS?

Do institutionals & insiders believe in NERV or ABUS?

Is NERV or ABUS more profitable?

Which has better valuation and earnings, NERV or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools